# US 5,344,657 A · Microbeads of diltiazem, a process for their manufacture and a substained-release pharmaceutical composition containing them > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 5,344,657 A - Document ID: US5344657A - Status: Granted - Kind: A - Application number: 08/043,592 - Filed: 1993-04-05 - Granted: 1994-09-06 - Earliest claimed: 1988-04-27 - Assignees: Elf Sanofi - Inventors: Henri Desmolin - Web page: https://patentgrep.com/patent/US5344657A ## CPC - A61K 31/55: having seven-membered rings, e.g. azelastine, pentylenetetrazole - A61K 9/5078: {with drug-free core} - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) ## Abstract The microbeads are composed of a core containing the active ingredient and a microporous membrane, insoluble in aqueous medium, consisting of a film-forming polymer, a plasticizer and a filling material. The membrane has a thickness such that diltiazem is released in vitro at an approximately constant rate for at least 6 hours after a latent period of less than one hour. The active ingredient can be intimately mixed with the core or included in a polyvinyl pyrrolidone layer coating an inert grain. The sustained-release microbeads are formed by application to the core of a dispersion of the constituents of the membrane in a solvent and evaporation of the solvent. The pharmaceutical compositions consist of capsules containing the microbeads. They are administered orally one or twice per day, depending on the dose, for the treatment of angina or hypertension. ## Claims ### Claim 1 Sustained-release diltiazem microbeads each of which comprises (a) a core including an inert grain substrate coated with a layer of the active ingredient combined with a binder surrounded by (b) a microporous membrane consisting essentially of a film-forming polymer insoluble in aqueous medium, a plasticizing agent, representing from 10 to 30% by weight of said film-forming agent, and a filling material representing 35 to 75% by weight of said membrane, wherein, as determined in vitro at a pH of between 1.5 and 7, a diltiazem release rate of approximately 10% per hour for at least 6 hours is attained after a latent period of less than one hour. ### Claim 2 (depends on 1) Microbeads according to claim 1, wherein the active ingredient is a water soluble salt of diltiazem. ### Claim 3 (depends on 1) Microbeads according to claim 1, wherein the active ingredient is diltiazem hydrochloride. ### Claim 4 (depends on 1) Microbeads according to claim 1, wherein the film forming polymer is selected from polyacrylates, polymethacrylates and alkylcelluloses. ### Claim 5 (depends on 4) Microbeads according to claim 4, wherein the film forming polymer is ethylcellulose. ### Claim 6 (depends on 5) Microbeads according to claim 5, wherein the ethylcellulose has a viscosity between 10 and 50 mPa.s. ### Claim 7 (depends on 1) Microbeads according to claim 1, wherein the filling material is selected from talc, silica, metal silicates, kaolin, lactose, sucrose and metal oxides. ### Claim 8 (depends on 7) Microbeads according to claim 7, wherein the filling material is talc. ### Claim 9 (depends on 1) Microbeads according to claim 1, wherein the plasticizing agent is castor oil. ### Claim 10 (depends on 1) Microbeads according to claim 1, wherein the active ingredient is diltiazem hydrochloride, the film forming polymer is selected from polyacrylates, polymethacrylates and alkylcelluloses and the filling material is selected from talc, silica, metal silicates, kaolin, lactose, sucrose and metal oxides. ### Claim 11 (depends on 1) Microbeads according to claim 1, wherein the active ingredient is diltiazem hydrochloride, the film forming polymer is ethylcellulose and the filling material is talc. ### Claim 12 (depends on 1) Microbeads according to claim 1, wherein the membrane consists of 25 to 40% by weight of ethylcellulose, from 5 to 10% by weight of castor oil and from 50 to 70% by weight of talc. ### Claim 13 (depends on 1) Microbeads according to claim 1, wherein the binder is polyvinyl pyrrolidone. ### Claim 14 (depends on 1) Microbeads according to claim 1, having a diameter from 0.4 to 1.4 mm, wherein the active ingredient is diltiazem hydrochloride, and wherein the membrane has a thickness of from 15 micrometers to 60 micrometers and consists essentially of 25 to 40% by weight of ethylcellulose, from 5 to 10% by weight of plasticizing agent and from 50 to 70% by weight of talc. ### Claim 15 (depends on 1) A process for the preparation of the microbeads according to claim 1, wherein the membrane is applied to the core by the spraying of a dispersion of its components in a solvent. ### Claim 16 (depends on 1) A sustained-release pharmaceutical composition of diltiazem, consisting essentially of capsules containing microbeads according to claim 1. ### Claim 17 (depends on 16) A pharmaceutical composition according to claim 16, wherein the capsule contains from 100 to 600 microbeads. ### Claim 18 (depends on 17) A pharmaceutical composition according to claim 17, wherein the capsule contains from 90 to 350 mg of diltiazem.